Abstract
Twelve male subjects, aged 19 to 40 years, shown to be healthy by examination and laboratory tests, took 500 mg of ciprofloxacin every 12 h for 7 days. After the first and the last dose, blood and urine samples were taken and drug concentrations were determined by bioassay. There was a significant buildup in mean concentrations in serum from day 1 to day 7; mean peak levels (attained after 1 to 2 h) were 1.9 and 2.8 micrograms/ml, respectively. The terminal half-life was 3.5 to 4 h. About 40% of the drug was excreted into the urine during the 12-h period after dosing; minimum mean concentrations in urine were 105 micrograms/ml on day 1 and 174 micrograms/ml on day 7. Considerable amounts of ciprofloxacin were found in the feces on day 7 (185 to 2,220 micrograms/g). Marked changes in the aerobic part of the fecal flora were observed as a result of taking ciprofloxacin: coliforms were absent on day 7, and concentrations of streptococci and staphylococci were significantly reduced. There was no overgrowth by yeasts. One week later the fecal flora had returned to a state similar to that found before treatment. Anaerobes were little affected quantitatively but acquired resistance to ciprofloxacin. Side effects were mild and transient.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Adhami Z. N., Wise R., Weston D., Crump B. The pharmacokinetics and tissue penetration of norfloxacin. J Antimicrob Chemother. 1984 Jan;13(1):87–92. doi: 10.1093/jac/13.1.87. [DOI] [PubMed] [Google Scholar]
- BRUMFITT W., PERCIVAL A., CARTER M. J. Treatment of urinary-tract infections with amphicillin. A clinical trial. Lancet. 1962 Jan 20;1(7221):130–133. doi: 10.1016/s0140-6736(62)91132-7. [DOI] [PubMed] [Google Scholar]
- Brumfitt W., Hamilton-Miller J. M. Rifaprim (rifampicin plus trimethoprim): pharmacokinetics and effects on the normal flora of man. Biopharm Drug Dispos. 1981 Apr-Jun;2(2):157–166. doi: 10.1002/bdd.2510020208. [DOI] [PubMed] [Google Scholar]
- Crowther J. S. Transport and storage of faeces for bacteriological examination. J Appl Bacteriol. 1971 Jun;34(2):477–483. doi: 10.1111/j.1365-2672.1971.tb02307.x. [DOI] [PubMed] [Google Scholar]
- Crump B., Wise R., Dent J. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother. 1983 Nov;24(5):784–786. doi: 10.1128/aac.24.5.784. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fass R. J. In vitro activity of ciprofloxacin (Bay o 9867). Antimicrob Agents Chemother. 1983 Oct;24(4):568–574. doi: 10.1128/aac.24.4.568. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Montay G., Goueffon Y., Roquet F. Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. Antimicrob Agents Chemother. 1984 Apr;25(4):463–472. doi: 10.1128/aac.25.4.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Reeves D. S., Bywater M. J., Holt H. A., White L. O. In-vitro studies with ciprofloxacin, a new 4-quinolone compound. J Antimicrob Chemother. 1984 Apr;13(4):333–346. doi: 10.1093/jac/13.4.333. [DOI] [PubMed] [Google Scholar]
- Wise R., Andrews J. M., Edwards L. J. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother. 1983 Apr;23(4):559–564. doi: 10.1128/aac.23.4.559. [DOI] [PMC free article] [PubMed] [Google Scholar]
- van der Waaij D. Colonization resistance of the digestive tract: clinical consequences and implications. J Antimicrob Chemother. 1982 Oct;10(4):263–270. doi: 10.1093/jac/10.4.263. [DOI] [PubMed] [Google Scholar]